Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

BPH

Combination therapy—a strategy for BPH-related progression

Nature Reviews Urology volume 7, pages 239–240 (2010)Cite this article

Subjects

A randomized controlled trial published in European Urology concludes that combination therapy with tamsulosin and dutasteride is superior to monotherapy with either of these therapies in reducing the risk of clinical progression of benign prostatic hyperplasia. This approach might prove an attractive option for men who have troublesome symptoms and wish to avoid surgery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Roehrborn, C. G. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 57, 123–131 (2010).

    Article  CAS  PubMed  Google Scholar 

  2. Eberth, B., Watson, V., Ryan, M., Hughes, J. & Barnett, G. Does one size fit all? Investigating heterogeneity in men's preferences for benign prostatic hyperplasia treatment using mixed logit analysis. Med. Decis. Making 29, 707–715 (2009).

    Article  PubMed  Google Scholar 

  3. McConnell, J. D. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349, 2387–2398 (2003).

    Article  CAS  PubMed  Google Scholar 

  4. Emberton, M. et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 61, 267–273 (2003).

    Article  PubMed  Google Scholar 

  5. Sculpher, M. et al. Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ 328, 382 (2004).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

M. Emberton receives research support from UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Center.

Author information

Authors and Affiliations

  1. Department of Urology, 2a Maples House, University College Hospital, 235 Euston Road, NW1 2BU, London, UK

    Mark Emberton

Authors
  1. Mark Emberton
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

M. Emberton declares that he has acted as a consultant and has received speakers bureau (honoraria) and grant/research support from GlaxoSmithKline.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Emberton, M. Combination therapy—a strategy for BPH-related progression. Nat Rev Urol 7, 239–240 (2010). https://doi.org/10.1038/nrurol.2010.48

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.48

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing